Gilead Sciences and Lakefront Biotherapeutics have closed their joint acquisition of Ouro Medicines, expanding both companies' inflammation pipelines and repositioning Lakefront at the centre of European biotech consolidation.1
The Ouro portfolio will now form the foundation of Lakefront's R&D pipeline — a decisive move for the company formerly known as Galapagos, which has been rebuilding its asset base since its strategic pivot.1 Alongside the Ouro integration, Lakefront co-develops gamgertamig with Gilead, adding an active clinical collaboration with one of the sector's largest acquirers.1
Capital structure preserved
Despite the deal activity, Lakefront retains approximately €2 billion in deployable capital.1 The transaction structure preserves real independence: at least $500 million can be deployed without Gilead's involvement, outside the OLCA and Ouro transaction framework.1 Up to $150 million of that sum is earmarked for share buybacks.1
That capital cushion positions Lakefront as an active dealmaker in a sector under structural pressure. JAKAFI's 2028 patent cliff is pushing incumbents to acquire replacement assets in inflammation and hematology — precisely the space Ouro occupies.1
Clinical momentum at EHA 2026
The deal closes as EHA 2026 delivers a cluster of Phase 2/3 readouts across T-cell engagers, in vivo CAR-T, and JAK2 inhibitors, signalling that next-generation immunology platforms are maturing toward commercial viability.1 Regulatory timelines are tightening: ifinatamab deruxtecan carries an October 2026 FDA PDUFA date, and Awiqli's U.S. launch is imminent.1
Nanobiotix reported a 57.1% complete response rate (4/7 patients) in its CONVERGE Part 1 cohort at ESTRO 2026, against a standard-of-care baseline below 5% in Stage 3 inoperable NSCLC.2 VERAXA Biotech is advancing bispecific T-cell engagers and bispecific ADCs under a stated quality-by-design platform.3
A replicable European model
For mid-cap European biotechs, Lakefront's architecture — a Gilead co-development agreement, an acquired pipeline seeded by Ouro, and a preserved cash position — offers a replicable template. As U.S. incumbents face looming patent cliffs and next-generation modalities reach Phase 3, European companies with capital flexibility are increasingly positioned to compete on deal terms and pipeline depth.
